Coronary Artery Disease

Highlights Hub

Expert Highlights & Perspectives

Watch as experts Deepak Bhatt, MD, Prof. Gabriel Steg, MD and Lawrence Leiter, MD, discuss additional clinical pearls on the prevention of atherothrombotic events in high-risk diabetes patients with coronary artery disease (CAD).

Diabetes and the Increase Risk of Atherothrombotic Events
  • Increased platelet aggregation & activation in diabetes patients
  • Reduced responsiveness to commonly-used antiplatelet agents
  • The role of antiplatelet therapy in patients with diabetes
  • Summary and contextualization of THEMIS & THEMIS-PCI trials
How Do These Advances Fit in With Existing Therapies and Other Updates in Secondary Prevention in Diabetes Patients?
  • Going beyond glucose in diabetes
  • Multifactorial risk reduction
  • SGLT-2 inhibitors & recent updates
Advances in Dual Pathway Inhibition in Diabetes Patients
  • Overlap between dual antiplatelet therapy (DAPT) and dual pathway inhibition (DPI)
  • Which form of double antithrombotic agent/regimen should be used in patient
  • Integrating and interpreting the data from COMPASS and THEMIS/THEMIS-PCI